Skip to main content

Tweets

In Norway incidence of #SLE is decreasing, esp in women 50-59 years. Population study of 1558 confirmed SLE; 797 had new-onset betw 1999-2017. In older women 50-59 yrs incidence fell 3.4 to 1.1/100K (also 74% reduction in menopausal HRT https://t.co/Z1falNwLlD https://t.co/bJ3cXKueKg
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Small study of 33 #AAV pts and 21 controls shows nailfold capillaroscopy of no value in diagnosing/assessing AAV pts. https://t.co/uRFDBbLVJq https://t.co/pVETSFlBsp
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Poorly documented Dz activity in SpA. AI EHR analysis of 3 Hospitals found 758 pts (328 axSpA, 365 PsA, 65 non-classified SpA). Only 35% axSpA had ASDAS or BASDAI. DAPSA or DAS-28 in only 17% PsA. TJC/SJC in ~20% axSpA & ~32% of PsA https://t.co/OrLdK5k2lN https://t.co/bKjancBG4r
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest https://t.co/zJ9583vllj https://t.co/M1oKAcnqSH
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/RdLUvW3W7v https://t.co/CcQXQYwu7J
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Marketscan claims data shows Frailty as predictor for serious infxn in RA pts Rx w/ b/tsDMARDs. Among 57,980 RA pts (age 48 yrs), 6% were "frail" - this assoc w/ increased risk of serious infections (aHR 1.5) & inpatient hosp (1.4)https://t.co/cvcqE3KQmV https://t.co/We9uwMdt5Y
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/uRYKmtUdsZ https://t.co/5XdBVDfgYV
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Chinese Phase 2b RCT of telitacicept (TACI-Fc fusion protein inhibits both BAFF & APRIL) 3 doses vs PBO in 249 active SLE pts. Wk 48 SRI-4 response favored TELI (76% 240 mg, 68% 160 mg, 71% 80 mg vs 34% w/ PBO (all p<0.001) https://t.co/fz4W1le4Db https://t.co/0mTC4gQcdr
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Congratulations to Professor Paul Emery OBE on being named CBE: Commander of the Most Excellent Order of the British Empire for his research and advances in rheumatology. He is the Versus Arthritis Professor of Rheumatology, Leeds Institute https://t.co/xeJu05q3q8 https://t.co/VvKmHHf0iv
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Dr. Sidney Wolfe, longtime US consumer health watchdog & advocate for affordable care & oversight of drug safety died on 1/1/24 of brain cancer at age 86. Dr. Wolf once ran the Health Research Group at Public Citizen, a Wash, DC consumer advocacy group https://t.co/e4lyDglx3n https://t.co/VyLMXJi4ZZ
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
Best of 2023: New ACR RA-ILD Treatment Guidelines – What Were They Smoking!? Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients. https://t.co/6RFBjVkmXj https://t.co/Qvquu7ruKY
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
AutoAbs in poly/dermatomyositis - ANA+ 50% to 80%, but not helpful in Dx. Look for MSA Abs - espec antisynthetase ABs (anti-Jo-1), but also newer Abs: MDA-5, TIFF-1 gamma, NXP-2 (to be discussed #RNL24 Dr. Christopher-Stine) https://t.co/l46JHMWJby https://t.co/rZco5BMUJ5 https://t.co/2K9bidzLpt
Dr. John Cush @RheumNow ( View Tweet )
2 years 5 months ago
×